Allogeneic Human Mesenchymal Stem Cell Therapy (Remestemcel-L, Prochymal) as a Rescue Agent for Severe Refractory Acute Graft-versus-Host Disease in Pediatric Patients
Joanne Kurtzberg(Duke University), Sonali Chaudhury(Northwestern University), Eneida R. Nemecek(Oregon Health & Science University), Susan E. Prockop(Memorial Sloan Kettering Cancer Center), Victor Lewis(Alberta Children's Hospital), Lolie C. Yu(Louisiana State University), Julie‐An Talano(Dana-Farber Cancer Institute), Biljana Horn(UF Health Shands Hospital), Henrique Bittencourt(Centre Hospitalier Universitaire Sainte-Justine), Charles R. Mills(Osiris Therapeutics (United States)), Ka Wah Chan(Methodist Children’s Hospital), Pierre Teira(Université de Montréal)
Cited by 248
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
|Nature Medicine|2018|577
Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis
|Blood|2016|554
Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research
|Biology of Blood and Marrow Transplantation|2014|442